HepaRegeniX Initiates Phase Ib Trial of HRX-215, Aiming to Boost Liver Regeneration
HepaRegeniX GmbH has announced the dosing of the first patient in its Phase Ib clinical trial of HRX-215, a novel small-molecule inhibitor designed to promote liver regeneration. This marks a…